Published in Oncogene on January 27, 2000
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest (2001) 2.21
Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell (2012) 1.94
Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation. Mol Biol Cell (2005) 1.45
A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol Cell Biol (2003) 1.03
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzyme Regul (2007) 1.01
Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. Clin Exp Metastasis (2003) 0.89
Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis. Adv Enzyme Regul (2007) 0.89
Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder. PLoS One (2011) 0.87
Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence. Cell Death Dis (2014) 0.84
Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD(+)-dependent deacetylases. Oncogene (2014) 0.79
The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett (2016) 0.77
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell (1984) 8.32
Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science (1994) 6.07
Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev (1998) 5.14
Seat belts in pregnancy. BMJ (1992) 4.55
Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol (1997) 4.36
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia (2003) 3.89
SK&F 96365, a novel inhibitor of receptor-mediated calcium entry. Biochem J (1990) 3.86
Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol (1990) 3.55
Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol Cell Biol (1998) 3.23
Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Mol Cell Biol (1993) 3.13
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia (2003) 2.89
Functional and structural diversity of the human Dickkopf gene family. Gene (1999) 2.82
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res (2001) 2.78
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia (2004) 2.76
Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev (2000) 2.62
Molecular basis for the contribution of the antioxidant responsive element to cancer chemoprevention. Cancer Lett (2001) 2.57
Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev (2001) 2.56
Molecular analysis of a human interferon-inducible gene family. Eur J Biochem (1991) 2.46
The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem Soc Trans (2000) 2.40
Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell (2000) 2.30
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia (2008) 2.07
Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods (1993) 1.96
Inhibition of T cell receptor expression and function in immature CD4+CD8+ cells by CD4. Science (1990) 1.89
Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev (1997) 1.88
Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol (1995) 1.87
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia (2008) 1.79
Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes. Genes Dev (1995) 1.79
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene (2008) 1.73
Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. Mol Cell Biol (1997) 1.69
Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther (2008) 1.60
DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J Exp Med (2000) 1.59
Human 2-5A synthetase: characterization of a novel cDNA and corresponding gene structure. EMBO J (1985) 1.59
Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells. Am J Respir Cell Mol Biol (1999) 1.58
A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med (2000) 1.58
Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene (2012) 1.57
Dietary compliance and cardiovascular risk reduction with a prepared meal plan compared with a self-selected diet. Am J Clin Nutr (1997) 1.57
Use of fluo-3 to measure cytosolic Ca2+ in platelets and neutrophils. Loading cells with the dye, calibration of traces, measurements in the presence of plasma, and buffering of cytosolic Ca2+. Biochem J (1990) 1.56
Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia (2003) 1.56
The challenge of patients' unmet palliative care needs in the final stages of chronic illness. Palliat Med (2007) 1.54
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia (2011) 1.51
Toxigenic Vibrio cholerae O1 and cargo ships entering Gulf of Mexico. Lancet (1992) 1.51
Induced expression of Rnd3 is associated with transformation of polarized epithelial cells by the Raf-MEK-extracellular signal-regulated kinase pathway. Mol Cell Biol (2000) 1.47
A review of the biological properties and metabolic disposition of the new analgesic agent, meptazinol. Gen Pharmacol (1978) 1.47
Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr Biol (1996) 1.47
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia (2011) 1.45
The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers. Br J Clin Pharmacol (1977) 1.44
Raf-1 kinase activity is necessary and sufficient for gene expression changes but not sufficient for cellular morphology changes associated with cardiac myocyte hypertrophy. J Biol Chem (1994) 1.42
Morphology of the unfixed cochlea. Hear Res (1998) 1.41
Diagnostic utility of tomographic myocardial perfusion imaging with technetium 99m furifosmin (Q12) compared with thallium 201: results of a phase III multicenter trial. J Nucl Cardiol (1996) 1.40
The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation. Mol Cell Biol (1999) 1.39
PAMELA measurements of cosmic-ray proton and helium spectra. Science (2011) 1.39
Supporting dental registrants in difficulty. Br Dent J (2015) 1.39
Drug testing in Canadian jails: to what end? Can J Public Health (2000) 1.39
Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia (2003) 1.39
Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. Cell Growth Differ (2000) 1.38
Salmonella typhimurium DT170 in cattle. Vet Rec (2001) 1.38
Activation of Raf-1 and mitogen-activated protein kinase in murine macrophages partially mimics lipopolysaccharide-induced signaling events. J Exp Med (1995) 1.36
Interferon-induced gene expression in wild-type and interferon-resistant human lymphoblastoid (Daudi) cells. J Virol (1986) 1.31
An international outbreak of salmonellosis associated with raw almonds contaminated with a rare phage type of Salmonella enteritidis. J Food Prot (2005) 1.31
Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia (2007) 1.30
Erythropoietin induces Raf-1 activation and Raf-1 is required for erythropoietin-mediated proliferation. J Biol Chem (1991) 1.30
A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells. BMC Immunol (2001) 1.29
The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia (2002) 1.28
Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical fungus in a temperate environment. Can Commun Dis Rep (2008) 1.28
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia (2008) 1.27
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia (2011) 1.26
Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol (1993) 1.25
Novel post-translational regulation of TCR expression in CD4+CD8+ thymocytes influenced by CD4. Nature (1990) 1.24
Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. Biochem Biophys Res Commun (1992) 1.23
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem (2011) 1.22
Use of transgenic mice reveals cell-specific transformation by a simian virus 40 T-antigen amino-terminal mutant. Mol Cell Biol (1993) 1.20
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia (2007) 1.20
Failure of rapamycin to block proliferation once resting cells have entered the cell cycle despite inactivation of p70 S6 kinase. J Biol Chem (1993) 1.19
Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol (2001) 1.19
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem (2007) 1.19
Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src. Mol Cell Biol (1999) 1.18
Development of internal controls for PCR detection of Bacillus anthracis. Mol Cell Probes (1998) 1.18
Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene (2006) 1.17
Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest (1998) 1.17
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia (2012) 1.16
Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway. J Biol Chem (1996) 1.16